510(k) device
Nexpowder
Nextbiomedical Co., Ltd. · Hemostatic Device For Endoscopic Gastrointestinal Use (QAU, Class II) · First FDA decision Sep 16, 2022, newest Nov 27, 2024Gastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
7
Naming "Nexpowder"
MAUDE reports
3
Brand "Nexpowder", since 2015
PubMed studies
12
Mentioning "Nexpowder"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Nexpowder
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Nexpowder510(k)
K240994 · Decided Nov 27, 2024 · 230 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
- Nexpowder510(k)
K202929 · Decided Sep 16, 2022 · 717 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Nexpowder", any status and sponsor, newest update first.
- Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal BleedingPivotal-lookingRecruiting
Medtronic - MITGPublic (MDT)
NCT06188585 · 278 participants (planned) · Start Jun 21, 2024 · Primary completion Aug 2029
Device: UI-EWD; Conventional therapy · For: Acute Gastrointestinal Bleeding
Sites: New Haven, Connecticut; Chicago, Illinois; Boston, Massachusetts · 15 sites in all
- Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal TractNot yet recruiting
Next Biomedical Co., Ltd.Not on our public-company list
NCT06939907 · 60 participants (planned) · Start Jun 2025 · Primary completion Jun 2027
Device: Nexpowder™ · For: Lower Gastrointestinal Bleeding; Diverticular Bleeding
Sites: Cheongju-si, South Korea; Daejeon, South Korea; Gwangju, South Korea · 6 sites in all
- Effectiveness of 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal BleedingPivotal-lookingCompleted
Next Biomedical Co., Ltd.Not on our public-company list
NCT04124588 · 348 participants · Start Nov 1, 2018 · Primary completion Oct 12, 2021
Device: Nexpowder (Hemostatic powder); Conventional Technique · For: Nonvariceal Upper Gastrointestinal Bleeding
Sites: Gyeonggi-do, South Korea; Incheon, South Korea · 3 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Nexpowder", and for the whole product code for context.
This brand
3 reports: 3 malfunction, 0 injury, 0 death
Whole product code QAU
1,141 reports: 957 malfunction, 175 injury, 9 death
Newest reports for this brand
- NEXPOWDERMalfunction
MW5163800 · Received Dec 19, 2024 · Event dated Dec 5, 2024
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- NEXPOWDERMalfunction
20662050 · Received Nov 12, 2024 · Event dated Jul 19, 2024
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- NEXPOWDERMalfunction
17931078 · Received Oct 13, 2023 · Event dated Aug 1, 2023
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Nexpowder"[tiab]. The summary above synthesizes these.
- Topical hemostatic agents in endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review.
Gralnek IM, Bhandari P, Alkandari A, et al. · Endoscopy · 2025Systematic Review
- Prevention of rebleeding after primary haemostasis using haemostatic powder in non-variceal upper gastrointestinal bleeding: a multicentre randomised controlled trial.
Shin J, Cha B, Hong J, et al. · Gut · 2025Randomized Controlled Trial, Multicenter Study
- A starry sky image result in a patient with active bleeding due to malignancy cause.
Álvarez-García M, Blas L, Otegui L, et al. · Rev Esp Enferm Dig · 2025Case Reports
- UI-EWD hemostatic powder in the management of refractory lower gastrointestinal bleeding: a multicenter study.
Seong G, Cha B, Shin J, et al. · Scand J Gastroenterol · 2024Multicenter Study
- Hemostatic Powders in Non-Variceal Upper Gastrointestinal Bleeding: The Open Questions.
Paoluzi OA, Troncone E, De Cristofaro E, et al. · Medicina (Kaunas) · 2023Review
- Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding.
Cha B, Lee D, Shin J, et al. · BMC Gastroenterol · 2022
- Novel hemostatic adhesive powder to prevent delayed bleeding after endoscopic submucosal dissection in the GI tract: first U.S. multicenter experience.
Yang D, Bhatt A, Hayat M, et al. · IGIE · 2024
- Precise and optimal delivery techniques of hemostatic powders in gastrointestinal bleeding.
Chiang HC, Lin XZ · Clin Endosc · 2026Review
- Nexpowder After Colorectal ESD: A Promising Signal Requiring Cautious Interpretation.
Liao Y, Feng L · J Gastroenterol Hepatol · 2026Letter
- The Effect of Nexpowder in Reducing Post-ESD Coagulation Syndrome in Proximal Colon Lesions: A Retrospective Multicenter Study.
Lee WM, Shin J, Seong G, et al. · J Gastroenterol Hepatol · 2026Multicenter Study
- Response to: Nexpowder After Colorectal ESD: A Promising Signal Requiring Cautious Interpretation.
Lee WM, Shin J, Seong G, et al. · J Gastroenterol Hepatol · 2026Letter
- Prevention of Delayed Bleeding after Endoscopic Resection using Gel Hemostatic Powder: A Multicentric Open-lapel Prospective Study.
Rodriguez JC, Deprez PH, Bisschops R, et al. · Endosc Int Open · 2026
Other devices of this type
Also filed under product code QAU.
- Hemospray Endoscopic Hemostat (HEMO-[X])Wilson-Cook Medical, Inc. · De Novo 2026
- PuraStat3-D Matrix Europe SAS · 510(k) 2026
- PuraStat GI3-D Matrix, Inc. · 510(k) 2026
- Resolv Endoscopic Hemostat SystemHemostasis, LLC · 510(k) 2024
- PuraStat3-D Matrix, Inc. · 510(k) 2023
- PuraStat-GI3-D Matrix, Inc. · 510(k) 2021
- EndoClotEndoclot Plus Co., Ltd. · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.